Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (68)

2022

  1. The Effect of Teriparatide Treatment on the Risk of Fragility Fractures in Postmenopausal Women with Osteoporosis: Results from the Asian and Latin America Fracture Observational Study (ALAFOS)

    Calcified Tissue International, Vol. 110, Núm. 1, pp. 74-86

2021

  1. Teriparatide

    Osteoporotic Fracture and Systemic Skeletal Disorders: Mechanism, Assessment, and Treatment (Springer Nature), pp. 339-359

  2. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained

    Journal of Bone and Mineral Research, Vol. 36, Núm. 2, pp. 236-243

2020

  1. Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial

    Calcified Tissue International, Vol. 106, Núm. 6, pp. 646-654

  2. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials

    The Lancet Diabetes and Endocrinology, Vol. 8, Núm. 8, pp. 672-682

2019

  1. Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials

    Journal of Bone and Mineral Research, Vol. 34, Núm. 4, pp. 632-642

  2. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis

    Bone, Vol. 120, pp. 1-8

  3. Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies

    Calcified Tissue International, Vol. 104, Núm. 2, pp. 193-200

  4. Reply to: Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials

    Journal of Bone and Mineral Research

  5. Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS)

    Current Medical Research and Opinion, Vol. 35, Núm. 6, pp. 1041-1049

2018

  1. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)

    Calcified Tissue International, Vol. 103, Núm. 4, pp. 359-371

  2. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies

    Bone, Vol. 116, pp. 58-66

  3. Teriparatide Treatment Increases Mineral Content and Volume in Cortical and Trabecular Bone of Iliac Crest: A Comparison of Infrared Imaging With X-Ray–Based Bone Assessment Techniques

    Journal of Bone and Mineral Research, Vol. 33, Núm. 12, pp. 2230-2235

2017

  1. Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial

    Journal of Bone and Mineral Research, Vol. 32, Núm. 5, pp. 1040-1051

2016

  1. Effects of teriparatide compared with risedronate on recovery after pertrochanteric hip fracture results of a randomized, active-controlled, double-blind clinical trial at 26 weeks

    Journal of Bone and Joint Surgery - American Volume, Vol. 98, Núm. 22, pp. 1868-1878

  2. Effets du tériparatide et du risédronate sur la DMO et la consolidation fracturaire chez des patients âgés avec fracture pertrochantérique récente: Résultats finaux d'un essai clinique randomisé de 78 semaines

    Revue du Rhumatisme (Edition Francaise), Vol. 83, pp. A83-A84

  3. Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS)

    Calcified Tissue International, Vol. 99, Núm. 3, pp. 259-271

  4. Fracture rate, back pain and quality of life in patients with osteoporosis treated with teriparatide: Results of the European observational study ExFOS (Extended Forsteo® Observational Study)

    Revue du Rhumatisme (Edition Francaise), Vol. 83, pp. A188-A189

  5. Teriparatide for osteoporosis: Importance of the full course

    Osteoporosis International, Vol. 27, Núm. 8, pp. 2395-2410

2015

  1. Predictive ability of heel quantitative ultrasound for incident fractures: an individual-level meta-analysis

    Osteoporosis International, Vol. 26, Núm. 7, pp. 1979-1987